Projection of the incidence of breast cancer in France in 2018;Projection de l'incidence du cancer du sein en 2018 en France

Bulletin du Cancer

Volumn 97, Issue 3, 2010, Pages 293-299

  Bouee S ^a   Grosclaude, P ^b   Alfonsi, A ^c   Florentin, V ^c   Clavel Chapelon, F ^d   Fagnani, F ^a  

^a CEMKA EVAL   (France)

^b Registre des Cancers du Tarn   (France)

^c Laboratoires Roche   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Breast cancer; Hormone therapy for menopause; Incidence; Projection

Indexed keywords

AGE DISTRIBUTION; AGING; ARTICLE; BREAST CANCER; CANCER INCIDENCE; COHORT ANALYSIS; FRANCE; HORMONAL THERAPY; HUMAN; MENOPAUSE; POPULATION GROWTH; POPULATION SIZE; AGE; BREAST TUMOR; EPIDEMIOLOGY; ESTROGEN THERAPY; FEMALE; FORECASTING; INCIDENCE; POPULATION DYNAMICS; STATISTICAL MODEL; UTILIZATION REVIEW;

AGE FACTORS; BREAST NEOPLASMS; COHORT EFFECT; ESTROGEN REPLACEMENT THERAPY; FEMALE; FORECASTING; FRANCE; HUMANS; INCIDENCE; MENOPAUSE; MODELS, STATISTICAL; POPULATION DYNAMICS;

EID: 77950365658     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1046     Document Type: Article

References (39)

1. Tables de mortalité : http://www.cepidc.vesinet.inserm.fr/inserm/ html/pages/informations-cepidc-fr.htm.
2. Belot A, Velten M, Grosclaude P, Bossard N, Launoy G, Remontet L, et al. Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2005. Saint-Maurice (Fra) : Institut de veille sanitaire, décembre 2008, 132p.
3. Eilstein D, Uhry Z, Lim TA, Bloch J. Lung cancer mortality in France. Trend analysis and projection between 1975 and 2012, using a Bayesian age-period-cohort model. Lung Cancer 2008 ; 59 : 282-290
4. Eilstein D, Quoix E, Hedelin G. Incidence du cancer du poumon dans le Bas-Rhin : tendance et projections en 2014 (Incidence of lung cancer in Bas-Rhin, France: trend and projection for 2014). Rev Mal Respir 2006 ; 23 : 115-117
5. Dyba T, Hakulinen T. Comparison of different approaches to incidence prediction based on simple interpolation techniques. Stat Med 2000 ; 19 : 1741-1752 (Pubitemid 30436060)
6. Bray I. Application of Markov Chain Monte Carlo methods to projecting cancer incidence and mortality. Appl Statist 2002 ; 51 : 151-163
7. Section B7 : hormone replacement therapy and oral contraceptives. In: Attributable causes of cancer in France in the year 2000. IARC 2007. ISBN : 978 92 832 2443 4. 69: 84.
8. Allemand H, Seradour B,Weill A, Ricordeau P. Baisse de l'incidence des cancers du sein en 2005 et 2006 en France : un phénomène paradoxal. Bull Cancer 2008 ; 95 : 11-15
9. Ringa V, Fournier A. Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)? Rev Epidemiol Sante Publique 2008 ; 56 : 297-301.
10. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 2006 ; 332 : 689-692
11. Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008 ; 168 : 2311-2316
12. http://www.ined.fr/fichier/t-telechargement/10907/telechargement-fichier- fr-telepopjeune.xls.
13. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I. Age-period and age-cohort models. Stat Med 1987 ; 6 : 449-467
14. Belot P, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al. Cancer incidence and mortality over the period 1980-2005. Rev Epidemiol Sante Publique 2008 ; 56 : 159-175
15. Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Estimations nationales : tendances de l'incidence et de la mortalité par cancer en France entre 1978 et 2000. BEH 2003 ; 41 : 190-193
16. Remontet L, Buemi A, Velten M, Jougla E, Estève J. Évolution de l'incidence et de la mortalité par cancer en France de 1978 à 2000. Avril 2003. http//www.invs.sante.fr.
17. http://www.invs.sante.fr/surveillance/cancers/estimations-cancers/ default.htm.
18. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N cohort. Int J Cancer 2005 ; 114 : 448-454 (Pubitemid 40279968)
19. Eilstein D, Quoix E, Hedelin G. Incidence du cancer du poumon dans le Bas-Rhin : tendance et projections en 2014 (Incidence of lung cancer in Bas-Rhin, France: trend and projection for 2014). Rev mal Respire 2006 ; 23 : 117-125
20. Holford TR, Zhang Z, McKay LA. Estimating age, period and cohort effects using the multistage model for cancer. Stat Med 1994 ; 13 : 23-41. (Pubitemid 24008786)
21. Moller B, Fekjaer H, Hakulinen T, Tryggvadottir L, Storm HH, Talback M, et al. Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev 2002 ; 11 (Suppl 1) : S1-96.
22. Bray I, Brennan P, Boffetta P. Recent trends and future projections of lymphoid neoplasm. A Bayesian age-period-cohort analysis. Cancer Causes Control 2001 ; 12 : 813-820
23. Cancers : pronostic à long terme. Expertise collective de l'Inserm, 2005.
24. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 ; 18 : 581-592
25. http://www.invs.sante.fr/applications/cancers/projections2009/default.htm
26. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005 ; 34 : 405-412
27. Estève J. Incidence du cancer du sein en France et dans les pays développés. Presse Med 2007 ; 36 : 315-321
28. Ziegler RG, Hoover RN, Pike MC. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993 ; 85 : 1819-1827 (Pubitemid 23333614)
29. Trétarre B, Guizard AV, Fontaine D ; les membres du réseau Francim et le CépiDc-Inserm. Cancer du sein chez la femme : incidence et mortalité, France 2000. BEH 2004 ; 44 : 209-210
30. Rochefort H, Rouëssé J. How to reduce the incidence of breast cancer. Bull Acad Natl Med 2008 ; 192 : 161-179
31. Minami Y, Tsubono Y, Nishino Y, Ohuchi N, Shibuya D, Hisamichi S. The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer 2004 ; 108 : 901-906 (Pubitemid 38112621)
32. Dépistage du cancer du sein : que peut-on dire aujourd'hui des bénéfices attendus ? INC InVS, septembre 2006. http://www.invs.sante.fr/publications/2006/cancer-sein-inca/cancer-sein-inca- invs.pdf.
33. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. Br J Cancer 1995 ; 71 : 898-899
34. http://www.invs.sante.fr/surveillance/cancers/default.htm.
35. Le Gales C, Fagnani F, Lefaure C. Le dépistage mammographique du cancer du sein : explosion des pratiques, multiplication des programmes. BEH 1990 ; 1 : 3.
36. CGHFBC, Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative analysis of data from 51 epidemiological studies of 52,705 women with beast cancer and 108,411 women without breast cancer. Lancet 1997 ; 350 : 1047-1059
37. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Non-cardiovascular disease outcomes during 6.8 years of hormone replacement therapy; Heart and Estrogen/ progesterone Replacement follow-up (HERS II). JAMA 2002 ; 288 : 58-66.
38. Chebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestogen on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003 ; 289 : 3243-3253 (Pubitemid 37430077)
39. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008 ; 107 : 103-111 (Pubitemid 350179584)